Long-Term Pentoxifylline Therapy and Cardiovascular Disease Risk in Diabetic Kidney Disease Patients
Author Information
Author(s): Wang Jie-Sian, Tsai Ping-Hsuan, Tseng Kuo-Feng, Lin Cheng-Li, Chen Fang-Yu, Chang Chiz-Tzung, Shen Ming-Yi
Primary Institution: China Medical University
Hypothesis
Does long-term pentoxifylline therapy reduce the risk of atherosclerotic cardiovascular disease in patients with diabetic kidney disease?
Conclusion
Long-term pentoxifylline therapy is associated with a 47% reduction in the risk of atherosclerotic cardiovascular disease in diabetic kidney disease patients.
Supporting Evidence
- Long-term pentoxifylline users had a 47% lower cumulative incidence of ASCVD compared to short-term users.
- Pentoxifylline treatment increased Klotho levels, which helps protect endothelial cells.
- Short-term pentoxifylline users had a higher risk of ASCVD compared to non-users.
Takeaway
Taking a medicine called pentoxifylline for a long time can help people with kidney problems and diabetes avoid heart disease.
Methodology
This retrospective cohort study analyzed data from 129,764 diabetic kidney disease patients to compare the effects of long-term versus short-term pentoxifylline therapy on cardiovascular disease risk.
Potential Biases
Potential residual confounding due to indirect measures of lifestyle factors like BMI, alcohol intake, and smoking.
Limitations
The study lacked detailed lipid profile data and relied on claims data, which may not capture all relevant patient characteristics.
Participant Demographics
Patients with diabetic kidney disease, aged 20 and older, without pre-existing cardiovascular disease.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 0.49–0.58
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website